Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
six-month functional patency of 89% vs 54% for AVF and 12-month secondary patency of 81% vs 48% (joint relative patency 1.65, p Safety profile: no infections or ruptures were reported for ATEV in V007, though rates of thrombosis, stenosis and pseudoaneurysm were higher than AVF but were mostly treatable (83% of women with thrombosis successfully managed). V012 interim results due in June: the women-focused phase III trial (target 150, 126 randomized) reached its interim milestone and Humacyte expects adjudicated interim data in the second week of June, with presentation planned at the SVS meeting on June 11; the primary endpoint is freedom from catheter over 12 months. Interested in Humacyte, Inc.? Here are five stocks we like better. Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program evaluating the company's acellular tissue engineered vessel (ATEV) as an alternative to autologous arteriovenous fistula
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
- Humacyte (HUMA) had its "buy" rating reaffirmed by BTIG Research. They now have a $3.00 price target on the stock.MarketBeat
- Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 [Yahoo! Finance]Yahoo! Finance
- Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026GlobeNewswire
- Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMAPR Newswire
HUMA
Earnings
- 3/27/26 - In-Line
HUMA
Sec Filings
- 4/28/26 - Form DEF
- 4/27/26 - Form SCHEDULE
- 4/24/26 - Form 8-K
- HUMA's page on the SEC website